NFKB1 and Miyoshi myopathy: The NF-κB pathway is frequently activated in MM through inactivation of negative regulators of the pathway (e.g. CYLD, TRAF3, BIRC2, BIRC3) or over-expression of positive regulators (e.g. NIK) [16–18].